Savara Says UK Regulator Accepts MOLBREEVI Application
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.K.’s Medicines and Healthcare products Regulatory Agency recently accepted its marketing authorization application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, …
Savara Says UK Regulator Accepts MOLBREEVI Application Read More